Consulta: creatorFacets:"Chamone,D.A.F."
Registros recuperados: 4
Data/hora: 02/06/2024 10:53:43

Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia
Provedor de dados: Brazilian Journal of Medical and Biological Research
Autores: Azevedo,M.C.; Velloso,E.D.R.P.; Buccheri,V.; Chamone,D.A.F.; Dorlhiac-Llacer,P.E.
In adults with non-promyelocytic acute myeloid leukemia (AML), high-dose cytarabine consolidation therapy has been shown to influence survival in selected patients, although the appropriate doses and schemes have not been defined. We evaluated survival after calculating the actual dose of cytarabine that patients received for consolidation therapy and divided them into 3 groups according to dose. We conducted a single-center, retrospective study involving 311 non-promyelocytic AML patients with a median age of 36 years (16-79 years) who received curative treatment between 1978 and 2007. The 131 patients who received cytarabine consolidation were assigned to study groups by their cytarabine dose protocol. Group 1 (n=69) received &lt;1.5 g/m2 every 12 h on 3...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Acute myeloid leukemia; Chemotherapy; Consolidation therapy; High-dose cytarabine; Prognosis.
Ano: 2015
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000200178

In vitro cytotoxicity of the LDE: daunorubicin complex in acute myelogenous leukemia blast cells
Provedor de dados: Brazilian Journal of Medical and Biological Research
Autores: Dorlhiac-Llacer,P.E.; Marquezini,M.V.; Toffoletto,O.; Carneiro,R.C.G.; Maranhão,R.C.; Chamone,D.A.F.
Acute myelogenous leukemia (AML) blast cells show high-affinity degradation of low-density lipoprotein (LDL), suggesting an increased expression of cellular LDL receptors. LDE is a lipid microemulsion easily synthesized in vitro which is known to mimic the metabolic pathway of LDL. We used LDE as a carrier for daunorubicin and assayed the cytotoxicity of the complex using AML blast cells since RT-PCR analysis showed that AML cells express LDL receptor mRNA. The LDE:daunorubicin complex killed 46.7% of blast cells and 20.2% of normal bone marrow cells (P&lt;0.001; Student t-test). Moreover, this complex destroyed AML blast cells as efficiently as free daunorubicin. Thus, LDE might be a suitable carrier of chemotherapeutic agents targeting these drugs to...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Cytotoxicity; Acute myelogenous leukemia; Daunorubicin; Low-density lipoprotein; LDE complex; RT-PCR.
Ano: 2001
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2001001000004

Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis
Provedor de dados: Brazilian Journal of Medical and Biological Research
Autores: Godoy,C.R.T.; Levy,D.; Giampaoli,V.; Chamone,D.A.F.; Bydlowski,S.P.; Pereira,J.
We measured circulating endothelial precursor cells (EPCs), activated circulating endothelial cells (aCECs), and mature circulating endothelial cells (mCECs) using four-color multiparametric flow cytometry in the peripheral blood of 84 chronic myeloid leukemia (CML) patients and 65 healthy controls; and vascular endothelial growth factor (VEGF) by quantitative real-time PCR in 50 CML patients and 32 healthy controls. Because of an increase in mCECs, the median percentage of CECs in CML blast crisis (0.0146%) was significantly higher than in healthy subjects (0.0059%, P&lt;0.01) and in the accelerated phase (0.0059%, P=0.01). There were no significant differences in the percentages of CECs in chronic- or active-phase patients and healthy subjects...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Circulating endothelial cells; Vascular endothelial growth factor; Chronic myeloid leukemia; Flow cytometry; Angiogenesis.
Ano: 2015
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000600509

Results of CHOP chemotherapy for diffuse large B-cell lymphoma
Provedor de dados: Brazilian Journal of Medical and Biological Research
Autores: Hallack Neto,A.E.; Pereira,J.; Beitler,B.; Chamone,D.A.F.; Llacer,P.D.; Dulley,F.L.; Macedo,M.C.M.A.; Chaoubah,A.
Patients with diffuse large B-cell lymphoma treated in a University Hospital were studied from 1990 to 2001. Two treatment regimens were used: ProMACE-CytaBOM and then, from November 1996 on, the CHOP regimen. Complete remission (CR), disease-free survival (DFS), and overall survival (OS) rates were determined. Primary refractory patients and relapsed patients were also assessed. A total of 111 patients under 60 years of age were assessed and ranked according to the international prognostic index adjusted to age. Twenty (18%) of them were classified as low risk, 40 (36%) as intermediate risk, 33 (29.7%) as high intermediate risk, and 18 (16.3%) as high risk. Over a five-year period, OS and DFS rates were 71 and 59%, respectively, for all patients. For the...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Diffuse large B-cell lymphoma; CHOP lymphoma treatment; ProMACE-CytaBOM treatment.
Ano: 2006
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006001000007